Neoadjuvant Systemic Therapy in Early Breast Cancer: Results of a Prospective Observational Multicenter BRIDE Study
Stefania Gori(Ospedale Sacro Cuore Don Calabria), Fabrizio Nicolis(Ospedale Sacro Cuore Don Calabria), Roberto Bordonaro(Ospedale Garibaldi), Saverio Cinieri(Ospedale A. Perrino), Angela Toss(University of Modena and Reggio Emilia), Patrizia Vici(Istituti di Ricovero e Cura a Carattere Scientifico), Elisabetta Cretella(Ospedale di Bolzano), Claudio Zamagni(Policlinico S.Orsola-Malpighi), Francesca Galli(University of Modena and Reggio Emilia), Claudia Bighin(Azienda Ospedaliera S.Maria), Catia Angiolini(Azienda Ospedaliero-Universitaria Careggi), M.F. Alvisi(Mario Negri Institute for Pharmacological Research), Alessandra Fabi(Agostino Gemelli University Polyclinic), Giancarlo Bisagni, Eliana Rulli(Mario Negri Institute for Pharmacological Research), Lucia Borgato, G. Ferretti(Istituti di Ricovero e Cura a Carattere Scientifico), C. Cappelletti, Irene De Simone(Mario Negri Institute for Pharmacological Research), Monica Turazza(Ospedale Sacro Cuore Don Calabria), Antonio Frassoldati(Italian Oncology Group of Clinical Research), Anna Santoni(Mario Negri Institute for Pharmacological Research), Alessandra Modena(Ospedale Sacro Cuore Don Calabria), Piermario Salvini, Anna Cariello(Azienda Unità Sanitaria Locale Della Romagna), Antonio Russo(University of Palermo), Matteo Valerio(Ospedale Sacro Cuore Don Calabria), Costanza De Rossi(Ospedale dell' Angelo), Lorenzo Gianni
Cited by 9
Related Papers
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|743
Preoperative Chemotherapy Plus Trastuzumab, Lapatinib, or Both in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer: Results of the Randomized Phase II CHER-LOB Study
|Journal of Clinical Oncology|2012|368